CA3010598A1 - Modulation of afucosylated species in a monoclonal antibody composition - Google Patents

Modulation of afucosylated species in a monoclonal antibody composition Download PDF

Info

Publication number
CA3010598A1
CA3010598A1 CA3010598A CA3010598A CA3010598A1 CA 3010598 A1 CA3010598 A1 CA 3010598A1 CA 3010598 A CA3010598 A CA 3010598A CA 3010598 A CA3010598 A CA 3010598A CA 3010598 A1 CA3010598 A1 CA 3010598A1
Authority
CA
Canada
Prior art keywords
culture
monoclonal antibody
glycan
fucose
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3010598A
Other languages
English (en)
French (fr)
Inventor
Marc Santoro
Kevin John JOSE
Sri MADABHUSHI
Scott Gangloff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Outlook Therapeutics Inc
Original Assignee
Oncobiologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57944513&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3010598(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncobiologics Inc filed Critical Oncobiologics Inc
Publication of CA3010598A1 publication Critical patent/CA3010598A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA3010598A 2016-01-06 2017-01-05 Modulation of afucosylated species in a monoclonal antibody composition Pending CA3010598A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662275384P 2016-01-06 2016-01-06
US62/275,384 2016-01-06
PCT/US2017/012349 WO2017120347A1 (en) 2016-01-06 2017-01-05 Modulation of afucosylated species in a monoclonal antibody composition

Publications (1)

Publication Number Publication Date
CA3010598A1 true CA3010598A1 (en) 2017-07-13

Family

ID=57944513

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3010598A Pending CA3010598A1 (en) 2016-01-06 2017-01-05 Modulation of afucosylated species in a monoclonal antibody composition

Country Status (8)

Country Link
US (1) US20190161543A1 (https=)
EP (1) EP3400241B1 (https=)
JP (1) JP6674028B2 (https=)
CN (1) CN109153716A (https=)
AU (1) AU2017206006B2 (https=)
CA (1) CA3010598A1 (https=)
MX (1) MX2018008447A (https=)
WO (1) WO2017120347A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3057616B1 (en) 2013-10-16 2020-03-11 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
US12325737B2 (en) * 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
HU231514B1 (hu) * 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
AU2019402923A1 (en) * 2018-12-19 2021-07-15 Seagen Inc. Controlled fucosylation of antibodies
WO2021066772A1 (en) * 2019-10-01 2021-04-08 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Cell culture medium for reducing fucosylation and basic variants in the production of antibodies
CN116964215A (zh) * 2021-02-12 2023-10-27 隆萨本德股份有限公司 用于调节抗体产物的无岩藻糖基化的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US8227241B2 (en) 2004-03-12 2012-07-24 Unigene Laboratories, Inc. Bacterial host cell for the direct expression of peptides
CA2608579C (en) 2005-05-26 2019-09-10 Cytos Biotechnology Ag Scalable fermentation process
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2009135181A2 (en) * 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US8409838B2 (en) 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
CA2763164A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
WO2013114165A1 (en) * 2012-01-30 2013-08-08 Dr Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased afucosylation content
NO2760138T3 (https=) * 2012-10-01 2018-08-04
WO2015140700A1 (en) * 2014-03-19 2015-09-24 Dr. Reddy's Laboratories Limited Cell culture process
ES2875274T3 (es) * 2015-11-02 2021-11-10 Hoffmann La Roche Procedimientos de preparación de formas fucosiladas y afucosiladas de una proteína

Also Published As

Publication number Publication date
EP3400241A1 (en) 2018-11-14
AU2017206006A1 (en) 2018-07-19
JP2019500876A (ja) 2019-01-17
CN109153716A (zh) 2019-01-04
US20190161543A1 (en) 2019-05-30
MX2018008447A (es) 2019-05-30
WO2017120347A1 (en) 2017-07-13
JP6674028B2 (ja) 2020-04-01
AU2017206006B2 (en) 2019-08-29
EP3400241B1 (en) 2020-07-22

Similar Documents

Publication Publication Date Title
AU2017206006B2 (en) Modulation of afucosylated species in a monoclonal antibody composition
US20190048070A1 (en) Reduction of high molecular weight species, acidic charge species and fragments in a monoclonal antibody composition
RU2018119112A (ru) Композиции и способы на основе dac hyp
JP2012244993A5 (https=)
JP2019514383A (ja) 細胞培養培地
TW200914614A (en) Cell culture method using amino acid-enriched medium
AU2014288811A1 (en) Improved process for production of monoclonal antibodies
CN112724259A (zh) 人血清白蛋白与白介素2的融合蛋白及其用途
CN110623921B (zh) 一种抗cd3和抗cd19的双特异性抗体注射制剂
CN105820248A (zh) 一种新型抗egfr单克隆抗体的制备方法及应用
EP2978498B1 (en) Protein production method
EP3601584A1 (en) Perfusion medium
EP3969564A1 (en) Method for reducing methionine oxidation in recombinant proteins
JP2022529502A (ja) 抗ｃｄ３８抗体および製剤
EP3374514A1 (en) Methods for modulating production profiles of recombinant proteins
CN107460221B (zh) 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法
US20130210075A1 (en) Enhanced protein expression
WO2017008736A1 (zh) 抗体依赖性细胞介导的细胞毒性增强的奥法木抗体
Kuyucu et al. Cell line development and bioreactor process optimization for an atezolizumab biosimilar
CA3246548A1 (en) Immunoconjugate preparation IL2
AU2015372704B2 (en) A method for controlling glycosylation of recombinant glycoprotein
CA3246301A1 (en) PREPARATION OF TNF.ALPHA IMMUNOCONJUGATES.
HK1138038A (en) Cell culture method using amino acid-enriched medium
HK1218893B (en) Protein production method

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211103

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240916

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250116

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250912

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260216